Uterine Papillary Serous Cancer (UPSC) is an uncommon type of endometrial cancer (less than 5% of all endometrial cancers). Histologically it resembles serous ovarian cancer and is characterised by very poor prognosis. Our study enrolled patients from 2005 to 2008 into a non-randomised phase 2 clinical trial examining the safety, feasibility and tolerability of radical surgery, followed by combination chemotherapy with Carboplatin and Paclitaxel, followed by radical radiotherapy to the pelvis. The results indicate that the triple-treatment is fairly well tolerated and its toxicity is acceptable. Most treatment-related adverse events occurred after chemotherapy. After 23 months follow up 14 patients recurred. Most patients recurred outside the radiation field. A subsequent trial should address the issue on how to make the systemic treatment more effective.